PARPs may be crushing it in the clinic, but half of doctors are still wary: executive

The red-hot class of PARP inhibitors showed up at this weekend’s European Society for Medical Oncology annual meeting, posting important—and impressive—data in multiple tumor types. But despite four drugs in the class and a wealth of studies supporting them, some doctors haven’t jumped on board.